Back to Search
Start Over
Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
- Source :
-
Journal of translational medicine [J Transl Med] 2018 Sep 04; Vol. 16 (1), pp. 247. Date of Electronic Publication: 2018 Sep 04. - Publication Year :
- 2018
-
Abstract
- We have previously reported that nuclear expression of the Hippo transducer TAZ in association with Wnt pathway mutations negatively impacts survival outcomes in advanced gastric cancer (GC) patients. Here, we extended these previous findings by investigating another oncogenic cooperation, namely, the interplay between YAP, the TAZ paralogue, and p53. The molecular output of the YAP-p53 cooperation is dependent on TP53 mutational status. In the absence of mutations, the YAP-p53 crosstalk elicits a pro-apoptotic response, whereas in the presence of TP53 mutations it activates a pro-proliferative transcriptional program. In order to study this phenomenon, we re-analyzed data from 83 advanced GC patients treated with chemotherapy whose tissue samples had been characterized for YAP expression (immunohistochemistry, IHC) and TP53 mutations (deep sequencing). In doing so, we generated a molecular model combining nuclear YAP expression in association with TP53 missense variants (YAP+/TP53 <superscript>mut(mv)</superscript> ). Surprisingly, this signature was associated with a decreased risk of disease progression (multivariate Cox for progression-free survival: HR 0.53, 95% CI 0.30-0.91, p = 0.022). The YAP+/TP53 <superscript>mut(mv)</superscript> model was also associated with better OS in the subgroup of patients who received chemotherapy beyond the first-line setting (multivariate Cox: HR 0.36, 95% CI 0.16-0.81, p = 0.013). Collectively, our findings suggest that the oncogenic cooperation between YAP and mutant p53 may translate into better survival outcomes. This apparent paradox can be explained by the pro-proliferative program triggered by YAP and mutant p53, that supposedly renders cancer cells more vulnerable to cytotoxic therapies.
- Subjects :
- Adaptor Proteins, Signal Transducing metabolism
Adult
Aged
Antineoplastic Agents therapeutic use
Cell Proliferation
Disease Progression
Disease-Free Survival
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
High-Throughput Nucleotide Sequencing
Humans
Male
Middle Aged
Mutation
Phosphoproteins metabolism
Proportional Hazards Models
Regression Analysis
Stomach Neoplasms mortality
Transcription Factors
Treatment Outcome
Tumor Suppressor Protein p53 metabolism
YAP-Signaling Proteins
Adaptor Proteins, Signal Transducing genetics
Mutation, Missense
Phosphoproteins genetics
Stomach Neoplasms genetics
Tumor Suppressor Protein p53 genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1479-5876
- Volume :
- 16
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of translational medicine
- Publication Type :
- Report
- Accession number :
- 30180862
- Full Text :
- https://doi.org/10.1186/s12967-018-1607-3